DAFTAR PUSTAKA
Adams,R.D., Victor, M., and Ropper, A.H. 2001. Principle of Neurology, 7th ed. Mc.Graw-Hill. New York.
Agustini,S., Khairani, A., Sitorus,F. 2010. Gambaran Stroke Pada Wanita di RSUPN Cipto Mangunkusumo. Dalam: Majalah Neurona. Perhimpunan Dokter Spesialis Saraf Indonesia. Jakarta. Hal:30-34.
Ahmed, S.H., Hu, C.J., Paczynski, R., Hsu, C.Y. 2001. Pathophysiology of ischemic injury. In: Fischer,M. editor. Stroke Therapy. 2 nd ed. Boston Butterworth- Heinemann.p. 25 – 49.
Ajjan. R.A., Standeven, K.F., Khanbhai,M., Phoenix,K.C., Gersch,J.W., Weisel,M.T. et al. 2009. Effects of Aspirin on Clot Structure and Fibrinolysis using a Novel in vitro cellular system. Arteriosclerosis, Thrombosis and Vascular Biology.2009.29:712-717.
Albala,B.B., Sacco,R.L. 2002. Modifiable risk factor for stroke: hypertension, diabetes mellitus, lipids, tobacco use, physical inactivuty, and alcohol. In: Gorelick, P.B., Alter, M., editors. The Prevention of Stroke. Boca Raton: The Parthenon Publishing Group.p. 21-37.
Altman, R., Luciardi, H.L., Muntaner, J., Herrera, R.N. 2004. The antithrombotic profile of aspirin. Aspirin resistence or simply failure.BioMed Thrombosis Journal.2: 1-8.
Ananyeva N.M., Kouiavskaia D.V., Shima M., and Saenko E.L.2002. Intrinsic pathway of blood coagulation contributes to thrombogenicity of atherosclerotic plaque. Blood.,99:4475-4485.
Antithrombotic Trialists Collaboration, 2002. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ.324:71-86.
Aono, Y., Ohkubo, T., Kikuya, M.,Hara, A., Kondo, T., Obara.,T. et al. 2007. Plasma Fibrinogen, Ambolatory Blood Pressure, and Silent Cerebrovascular Lesion: The Ohasama Study. Arterioscler Thromb Vasc Biol. 27 : 963-968.
Blake, G.J., Schmidtz,C., Lindpaintner, K., Ridker,P.M. 2001. Mutation in
the promoter region of the β-fibrinogen gene and the risk of future
Blann, A.D., Landray, M.J., Lip, G.Y.H. 2003. An of overview of antithrombotic therapy. In: Lip, G.Y.H, Blan, A.D. ABC of Antithrombotic therapy. BMJ Publishing Groups. Spain. p.10-13.
Bogousslavsky, J., Paciaroni, M., Agnelli, G., Caso, V. 2012. Manifestasions of Stroke. Karger. Switzerland.
Borissoff, J.I., Henri, M.H., Cate, H. 2011. The Hemostatic System as a Modulator of Atherosclerosis. The New England Journal of Medicine. 364: 1746-60.
Bielak LF, Klee GG, Sheedy PF, Turner ST, Schwartz RS, Peyser PA. 2000 Association of Fibrinogen With Quantity of Coronary Artery Calcification Measured by Electron Beam Computed Tomography.
Arterioscler Thromb Vasc Biol.20:2167-2171.
Brummel-Ziedins K, Orfeo T, Jenny NS, Everse SJ, Mann KG. 2004.Blood Coagulation and Fibrinolysis in Wintrobe’s Clinical Hematology, ed. 11, Chapt 21, Philadelphia: Lippincott Williams & Wilkins.
Caplan, L.R. 2000. Caplan’s stroke: A clinical Approach. 3rd ed. Butterworth-heinemann. Boston.
Chao, C.X., Tong, X.U., Wu,Z., Li, H., Qing, C.W. 2007. A meta-analysis of relationship between beta fibrinogen gene -148 C/T polymorphism and susceptibility to cerebral infarction in Han Chinese. Chin. Med. J. 120(13):1198-1202.
Chen,X.C., Xu, M.Y., Zhou, W., Han, C.L., Chen, W.Q. 2007. A meta analysis of beta fibrinogen gene -455 G/A polymorphism and plasma fibrinogen level in chinese cerebral infraction patients. Biomed environ Sci, 20(5): 366-72.
Chuang, S.Y., Bai, C.H., Chen, W.H., Lien, L.M., Pan, W.H. 2009. Fibrinogen Independently Predicts the Development of Ischemic Stroke in a Taiwanese Population. CVDFACTS Study. Stroke.40: 1578-1584.
Cook, N.S., Ubben, D. 1990. Fibrinogen as a major cardiovascular risk factor in cardiovascular disease. Trends Pharmacol Sci.11: 444-451.
Connor, J.M., Fowkes, F.G., Wood J, Smith, F.B., Donnan, P.T., Lowe, G.D. 1992. Genetic variation at fibrinogen loci and plasma fibrinogen levels. J Med Genet , 29:480–482.
Coull, B.M., Beamer,N., Garmo,P.,Sexton, G.,Nordt,F., Knox,R. et. al. 1991. Chronic blood hyperviscosity in subjects with acute stroke, transient ischemic attack, and risk factors for stroke. Stroke. 22:162-168.
Davi, G, Patrono, C. 2007. Platelet Activation and Atherothrombosis. The New England Journal of Medicine.357: 2482-94.
Davis, S.M., Donnan, G.A. 2012. Secondary Prevention after Ischemic Stroke or Transient Ischemic Attack. The New England Journal of Medicine. 166: 1914-22.
Del Zoppo, G.J, Waren D.L, Wasieswki, W.W., Pancioli, A.M., Demchuck, A.M., Trammel, J.,et al. 2009. Hiperfibrinogenemia andFunctional outcome from Acute Ischemic Stroke. Stroke; 40: 1687-1691.
Dewoto, H.R. 2007. Antikoagulan, antithrombotik. Trombolitik dan Hemostatik. Dalam: Gunawan, S.G., Setiabudy,R., Nafrialdi, Elysabeth. (Editor). Farmakologi dan Terapi. Departemen Farmakologi dan Terapeutik Fakultas Kedokteran- Universitas Indonesia. Balai Penerbit FK-UI, Jakarta. Hal. 813 – 814.
Dienner, H.C.2006. Update on Clopidogrel and dual anti-platelet therapy: neurology. European Heart Journal Supplements G, G15-G19.
DiCarlo, A., Lamassa, M., Baldereschi, M., Pracuci ,G., Basile, A.M., Wolfe, C.D., et al. 2003. Sex differences in the clinical presentation, Resources use, and 3 month outcome of Acute stroke in Europe; data from a multicenter multinational hospital-based registry. Stroke. 34 : 1114-1119.
DiMinno G, Silver MJ, Cerbone AM, Rainone A, Postiglione A, Mancini M. 1986 Increased Fibrinogen Binding to Platelets from Patients with Familial Hypercholesterolemia. Arteriosclerosis;6:203-211.
Di Napoli, M., Elkind, M.S., Godoy, D.A., Sigh, P., Papa, F., Popa wagner, A. 2011. Role of C reactive Protein in Cerebrovascular Disease. Expert Rev Cardiovasc Ther.9: 1565-1584.
Departemen Neurologi, R.S.U.P. Haji Adam Malik. 2011. Data penderita rawat inap tahun 2011.
El-Tarras,A.E., Awad, N.S., Said,M.M., Mitwaly,M. 2012. Detection of FXIII gene V34L and fibrinogen gene -455 G/A polymorphisms among Saudi Arabia population via polymerase chain reaction-reverse hybridization technique. African Journal Biotechnology.11(80): 14536-145411.
Ernst E, Matrai A, Scholzl C, Magyarosy I. 1987. Dose-effect relationship between smoking and blood rheology. Br J Haematol.,65: 485-7.
Ernst E, Matrai A, Marshall M. 1988. Blood rheology in patients with transient ischemic attacks. Stroke.19:634-6.
Ernst E, Koenig W, Matrai A, Filipiak B, Stieber J. 1988. Blood rheology in healthy cigarette smokers. Results from the MONICA Project, Augsburg. Arteriosclerosis. 8:385-8.
Ernst, E., Resch, K.L.,1993. Fibrinogen as cardiovascular risk factor: a meta analysis and review of the literature. Ann Intern Med,118:956-963.
Escobar, C.E., Harmening, D.M., Maier, D.M., Simmons, V.L., Smith-Moore, K.M., Wyrick-Glatzel,J.2002. Introduction to Hemostasis. In: Harmening, D.M. editors. Clinical Hematology and Fundamentals of Hemostasis. 4th edition. F.A. Davis Company. Philadelphia. p. 441-468.
Fatchiyah, Arumingtyas, E.L., Widyarti, S., Rahayu, S. 2011. Biologi Molekuler. Prinsip Dasar Analisis. Penerbit Erlangga.
Feher, M.D., Rampling, M.W., Brown, J., Robinson, R., Richmond, W.,Cholerton, S., Bain, B.J., Sever, P.S.1990. Acute changes in atherogenic and thrombogenic factors with cessation of smoking. J. Royal Socci Med. 83: 146-148.
Ferdinand,M., Van ‘t Hooft, Sara,J.F., Von Bahr., Angela Silveira., Abnastasia Iliadou.et al. 1999. Two common, Functional
Polymorphisms in the Promoter Region of the β-fibrinogen gene
Contribute to Regulation of Plasma Fibrinogen Concentration. Arteriosclerosis, Thrombosis and Vascular Biology.19:3063-3070.
Feinberg WM, Erickson LP, Bruck D, Kittelson J. 1996. Hemostatic Markers in Acute Ischemic Stroke. Stroke. 27:1296-1300.
Fergusson J.J. 2000. The Physiology of Normal Platelet Function. In:Fergusson J.J., Chronos N., Harrington, R.A eds. Antiplatelet Therapy in Clinical Practice. London. Martin Dunitz.p. 15-35.
Freeman,M.S., Mansfield,M.W., Barret,J.H., Grant, P.J. 2002. Genetic Controbution to Circulating Levels of Hemostatic Factors in Healthy Families with effects of known Genetic Polymorphisms on Heritability. Arterioscl Thromb Vasc Biol.22:506-510.
Furrie, B., Furrie,B.C. 2008. Mechanisms of Thrombus Formation. The New England Journal of Medicine.359: 938-49.
Guideline Stroke.2011. Pokdi Stroke. Perhimpunan Dokter Spesialis Saraf Indonesia (PERDOSSI). Jakarta.
Glass, S.K., Witztum, J.L. 2001. Atherosclerosis. The road Ahead cell. Springer-Wien. New York.
Goodman, T., Ferro,A., Sharma, P. 2008. Pharmacogenetics of aspirin resistence: a comprehensiv systematic review. British J Clin Pharmacol. 66(2): 222-232.
Goldstein, L.B., 2006. Guidelines for the Primary Prevention of Ischemic Stroke: A Guidelines From The American Heart Association/ American Stroke Association Stroke.37:1583-1633.
Gorman, M. 2000. Development and the rights of older people. In : Randal, J.eds. The ageing and development report: poverty, independence and the world’s older people. London. Earthscan Publication Ltd.p.3-21.
Griendling,K.K., Sorescu,D., Fukai, M.U. 2000. NAD(P)H oxidase. Role in Cardiovascular Biology and Disease. Cir. Res. 86: 494–501.
Hacke,W., Kaste, M, Bogousslavsky, J., Brainin, M., Gugging, M., Chamorro, A., Less,K., Leys, D., Kwiecinski, H., Toni, D. 2003. European Stroke Initiative: Ischemic Stroke Prophylaxis and Treatment. EUSI. Heidelberg.
Hall, R., Mazel, C.D. 2011. Antiplatelet Drugs: A Review of Their Pharmacology and Management in the Perioperative Period. Anethesia Analgesia.112: 293-318.
Hankey, G.J., Hacke, W., Easton, D., Johnston, S.E., Mas, J.L. 2010. Effect of Clopidogrel on the Rate and Functional Severity Stroke Among High Vascular Risk Patients. Stroke.41: 1679-1683.
Hamsten A, Iselius L, de Faire U, Blomback M. Genetic and cultural inheritance of plasma fibrinogen concentration. Lancet 1987; 2:988– 91.
Harmening, D.M. 2002. Clinical Hematology and Fundamentals of Hemostasis. 4th eds.F.A. Davis Company, Philadelphia.
Hills, N.K., Johnston, S.C. 2008. Trends in usage of alternative Antiplatelet Therapy after Stroke and Transicient Ischemic Attack. Stroke. 39: 1228-1232.
Hoffbrand,A.V., Pettit, J.E., Moss, P.A.H. 2002. Kapita selekta hematologi. EGC. Jakarta.
Hsieh, Y.C., Seshadri, S., Chung, W.T., Hsieh, F.I., Lin, H.J., Tseng, H.P. et al. 2012. Association between genetic variant on chromosome 12p13 and stroke survival and reccurence: one year prospective study in Taiwan. Journal of Biomedical Scence,19:1-8.
Humphries SE, Cook M, Dubowitz M, Stirling Y, 1987. Meade TW. Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet,1:1452-5.
Husted S. 2007. New Developments in oral antiplatelet therapy. European Heart Journal. Suplements.9: D20-D27.
Iacoviello L., Vischetti M., Zito F., Donati M.B. 2001. Genes encoding Fibrinogen and Cardiovascular Risk. Hypertension. 38: 1199-1203.
Ikram, M.A., Seshadri, S., Joshua, C.B., Fornage,M., DeStefano, A.L., Aulchenko, Y.S. et al. 2009. Genom wide Association Studies of Stroke. N.Engl. J. Med.360: 1718 – 28.
Ito U, Kuroiwa T, Nagasao J, Kawakami E, Oyanagi K.2006. Temporal Profiles of Axon Terminals, Synapses and Spines in the Ischemic Penumbra of the Cerebral Cortex Ultrastructure of Neuronal Remodeling. Stroke.37:2134-2139.
Jennifer Mc Dowell. 2006. Fibrinogen. Protein Data Bank. (http://www.ebi.ac.uk/interpro/potm/2006_11/Page1.htm) accessed on oktober 18, 2012.
Johnston,K.C., Wagner,D.P., Haley,C., Connors,J. 2002. Combined Clinical and Imaging Informations as an early Stroke outcome measure. Stroke.33:466-472.
Kamath S, Lip Gyh. 2003 .Fibrinogen; biochemistry, epidemiology and determinants, QJ Med ;96:711-729.
Katzung,B.G., Trevor, A.J., Masters, S.B. 2005. Katzung and Trevor’s Pharmacology, Examination and Board Review. 7th ed. Mc-Graw Hill. Boston.
Kavurma, M.M., Tan, N.Y., Bennet, M.R. 2008. Death Receptors and Their Ligands in Artheriosclerosis. Arterioscler Thromb Vasc Biol. 28: 1694-1702.
Kelompok Studi Serebrovaskuler dan Neurogeriatri Perdossi. 1999. Konsensus Nasional Pengelolaan Stroke di Indonesi. Perdossi Jakarta.
Kelompok Studi Stroke. 2007. Guideline Stroke. Perdossi. Jakarta.
Kessler, C., Spitzer,C., Stauske,D., Mende, S., Stadlmuller, J., Walther, R. Et al. 1997. The Apolipoprotein E and β fibrinogen G/A -455 gene plymorphism are associated with ischemic stroke involving large vessel disease. Arteriosclerosis, Thrombosis, and Vascular
Biology.17: 2880-2884.
Kita,Y., Okayama, A., Ueshima, H., Wada, M., Nozaki, A. Chondhury, S.R. Bonita, R., Inamoto, Y., Kasamatsu, T. 1999. Stroke Incidence and Case Fatality in Shiga, Japan. International J of Epidemiology. 28: 1059-1065.
Kiechl, S., Werner,P., Egger, G., Oberhollenzer, F., Mayr, M., Xu, Q. et al. 2002. Active and Passive smoking, Chronic Infection, and the Risk of Carotid Atheroscelrosis.Stroke.33: 2170-2176.
Koenig, W., Ernst E. 1992. The possible role of hemorheology in atherothrombogenesis. Atherosclerosis.94: 93-107.
Kolominsky-Rabas, P.L., Sarti C., Heuschmann, P.U., Graf, C., Siemonsen S., Neundoerfer B., Katalinic A., Lamg E., Gessman, K.G., Von Stockert, T.R. 1998. A Prospective Community Based Study of Stroke in Germany- The Erlangen Stroke Project (ESpro) incidence and case fatality at 1,3 and 12 month. Stroke. 29: 2501 – 2506.
Kumar, A., Sagar, R., Kumar, P., Sahu, J.K.,Grover, A., Srivastava, A.K., et al. 2013. Identification of genetic contribution to ischemic stroke by screening of single nucleotide polymorphisms in stroke patients by using a case control design. BMC Neurology.13: 136.
Krusius T., Hirvonen M., Vahtera E., Kala R. 1994. Short-term aspirin treatment does not reduce plasma fibrinogen concentration in young healthy adults. Thrombosis Research.6: 653-656.
Kwon,S., Hatzema,A.G., Duncan,P.W., Lai, S.M. 2004. Disability Measures in Stroke. Stroke.35:918:923.
Lameshow, S, Hosmer ,D, Klar, J, Lwanga, S, 1997. Besar Sampel dalam penelitian kesehatan, Terjemahan, Yogyakarta. Gajah Mada University Press.
Lam, K.S.L., Mar, O.C.K., Wat, N.M.S., Chan, L.C., Janus, E.D.1999. Fibrinogen gene G/A -455 polymorphism in relation to fibrinogen levels and ischaemic heart disease in Chinese patients with Type II diabetes. Diabetologia,42: 1250-1253.
Lai,S.M., Alter, M., Friday, G., Sobel. 1994. A Multifactorial Analysis of Risk Factors for Recurrence of Ischemic Stroke. Stroke. 25:958-962.
Lewin, B. 2000. Genes VII. 1st ed. Oxford University Press.New York.
Levenson J, Giral P, Razavian M, Gariepy J, Simon A. 1995 Fibrinogen and Silent Atherosclerosis in Subjects With Cardiovascular Risk Factors. Arteriosclerosis, Thrombosis, and Vascular Biology,
15:1263-68.
Lee, S.H., Kim, M.K.,Park, M.S., Choi, S.M., Kim, J.T., Kim, B.C., Cho, K.H. 2008. Beta Fibrinogen gene -455 G/A Polymorphism in Korea Ischemic Stroke Patients. J. Clin Neurol. 4(1): 17 – 22.
Liu, Y., Saha, N., Heng, C. K., Hong, S., Low, P. S. 2001. Fibrinogen genotypes ( and ) are associated with plasma fibrinogen levels in Chinese. JMG, 38:431.
Liu, Y., Pan, J., Wang, S., Li X., Huang,Y. 2002. Beta Fibrinogen gene -455 A/G polymorphism and plasma fibrinogen level in Chinese
Stroke patients. Chin. Med. J ( Engl).115 : 214-216.
Lisman,T. Weeterings,C., de Groot, P.G. 2005. Platelet aggregation: Involvement of thrombin and fibrinogen. Bioscience.10: 2504-2517.
Mackie, I.J., Kitchen, S., Machin, S.J., Lowe, G.D.O. 2003. Guidelines on Fibrinogen assay. British Journal of Haematology.121:396-404.
Martiskainen M., Pohjasvaara T., Mikkelsson J., Mantyla R., Kunnas T., Laippala P.,et.al. 2003. Fibrinogen Gene Promoter -455 A Allele as a Risk Factor for Lacunar Stroke. Stroke,34:886-91.
Martiskainen, M., Oksala, N., Pohjasvaara, T., Kaste, M, Oksala, A., Karhunen, P., et.al.. 2014. Beta-Fibrinogen gene promoter A-455 allele associated with poor longterm survival among 55 – 71 years old Caucasian women in Finnish stroke cohort. BMC,14:137.
Mauriello A., Sangiorgi G., Palmieri G., Virmani R., Holmes D.R. Jr., Schwartz R.S. et al. 2000. Hiperfibrinogenemia is associated with specific histocytological composition and complications of atherosclerotic carotid plaques in patients affected bt transient ischemic attacks. Circulation, 101(7): 744-50.
Meilahn, E.N., Cauley, J.A., Tracy, R.P., Macy, E.O., Gutai, J.P., Kuller, L.H. 1996. Association of sex hormone and adiposity with Plasma Levels of Fibrinogen and PAI-1 in Postmenopausal women. American Journal Epidemiology, 143(2): 159-166.
Meschia, J.F., Brott, T.G., Brown, Jr. R.D., Cook, R.J.P., Frankel, M., Hardy,J. et al. 2003. The Ischemic Stroke Genetics Study (ISGS) Protocol. BMC Neurology.3:4.
Michos, E.D., Ardehali, R., Blumenthal, R.S.,Lange,R.A., Ardehali, H. 2006. Aspirin and Clopidogrel resistence. Mayo Clin Proc.81 (4):518-526.
Milan,M., Sobrino, T., Castellanos, M., Nombela, F.Arenillas, J.F. Riva, E.
Mitchell, S.V., Helmi, L.L. 2011. Genetic and inflammatory Mechanism in Stroke. Diunduh dari: www. Medscape.com/ 19/3/2013.
Mirowska G.D., Gromadzka G., Mendel T., Janus L.B.,Dzierka J., Sarynzka D.I. et al. 2014. Impact of BDNF 196 G/A and BDNF -270 C/T polymorphisms on stroke rehabilitation outcome: sex and age differences. Stroke Rehabil, 21: S 33-41.
Misbach, J. 1999. Stroke: Aspek Diagnostik, Patofisiologi, Manajemen. Balai Penerbit FK-UI, Jakarta.
Misbach, J. 2011. Stroke: Aspek diagnostik, patofisiologi, manajemen. Badan Penerbit FK-UI, Jakarta.
Moake JL. 2002. Thrombotic Microangiopathies Mechanisms of Disease. N Engl J Med. 347(8):589-600.
Mosesson,M.W. 2005. Fibrinogen and fibrin structure and functions. Journal of Thrombosis and Haemostasis.3: 1894-1904.
Naito M, Funaki C, Hayashi T, Yamada K, Asai K, Yoshimine N, Kuzuya F. 1992 Substrate-bound fibrinogen, fibrin and other cell attachment-promoting proteins as a scaffold for cultured vascular smooth muscle cells. Atherosclerosis, 96:227–34.
Nan, Z., Xin, L., Yongqin, W., Xiaoqiu, L., Jiana, Li., Litian, Y. et al. 2012. Association of inflammatory gene polymorphisms with ischemic stroke in a Chinese Han population. Journal of Neuroinflamation, 9: 162.
Nasution D, 2007. Strategi Pencegahan Stroke Primer. Pidato Pengukuhan Jabatan Guru Besar tetap Neurologi Fakultas Kedokteran Universitas Sumatera Utara Medan.
Nedeltchev,K., Maur, T.A., Georgiadis,D., Arnold, M., Caso,V., Mattle H.P. et al. 2004. Ischemic stroke in young adults: predictors of outcome and recurrence. J. Neurol Neurosurg Psychiatry.76: 191-195.
Nishiuma S., Kario K., Yakushijin K. Maeda M., Murai R., Matsuo T., et al. 1998. Genetic Variation in the promoter region of the beta-fibrinogen gene is associated with ischemic stroke in Japanese Population.
Blood Coagul Fibrinolysis. 9: 373-79.
Obrenovitch T.P, Urenjak J., Wang M. 2003. Nitric Oxide Formation During Cortical Spreading Depression is critical for rapid subsequent recovery of ionic homeostasis. Journal of Cerebral Blood Flow & Metabolism.22: 680-688.
O’Donnel,M.J., Hankey, G.J., Eikelboom, J.W. 2008. Antiplatelet Therapy for Secondary Prevention of Noncardioembolic Ischemic Stroke. Stroke. 39: 1638-1646.
Ohira, T., Shahar,E., Chambless, L.E., Rosamond, W.D., Mosley, T.H., Folsom, A.R. 2006. Risk factor for is stroke subtype: The Atherosclerosis risk in community study. 37: 2493 – 2498.
Osterud, B., Bjorklid, E. 2003. Role of monocyte in atherogenesis. The American Phisiological Society. 83: 1069-1112.
Patrono,C.,Andreoti, F.,Arnesen, H.,Badimon,L., Baigent, C., Collet, J.P. et al.2011. Antiplatelet agents for the Treatment and Prevention of Aterothrombosis.(http://eurheartj.oxfordjournals.org/content/early/201 1/10/20/eurheartj.ehr373.full.pdf+html.) accessed on oktober 18, 2012.
Ponrácz E, Andrikovics H, Csornai M, Bernát IS, Nagy Z, 2006, Fibrinogen gene and of the Leiden mutation to hemorheological parameters in ischemic stroke, Clinical Hemorheology and Microcirculation, 35(1-2): 75-82.
Pohjasvaara,T., Erkinjuntti, T., Vataja, R., Kaste, M. 1997. Dementia three months After Stroke. 28: 785-792.
Prasetyo, E., Harris,S., Sitorus,F., Harqutanto.2011. Waktu kedatangan pasien Stroke di Lima Rumah Sakit Pemerintah di DKI Jakarta dan Faktor-Faktor Yang Mempengaruhinya. Dalam: Majalah Neurona. Perhimpunan Dokter Spesialis Saraf Indonesia. Hal.15-25.
Qizilbash N, Jones L, Warlow C, Mann J. 1991. Fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor ischaemic strokes. BMJ ,303:605-9.
Redman, C.M., Xia, H. 1999. Fibrinogen Biosynthesis Assembly, intracelullar Degradation, and Association with Lipid Synthesis and Secretion. Annals New York Academy of sciences. 480-495.
Rubattu, S., di Angelantonio, E., Nitsch, D., Gigante,B., Zanda, B. et al 2005. Polymorphisms in prothrombotic gene and their impact on ischemia stroke in Sardinian population. Thrombosis and Hemostasis.93(6): 1095-1100.
Robbins. 2007. Aterosklerosis. Dalam: Buku Ajar Patologi. Edisi 7, Volume 2. Penerbit EGC. Jakarta:369-378.
Rosenberg, R.D., Aird ,W.C. 1999. Vascular-Bed-Specific Hemostasis and Hypercoagulable States. N Engl J Med May,340(20):1555-64.
Rosenson, R.S., Tangney, C.C., Mosca, L.J.1998. Hormone Replacement Therapy Improves Cardiovascular Risk by Lowering Plasma Viscosity in Postmenopausal Women. Arterioscler Thromb Vasc Biol.
18:1902-1905.
Ross R. 1999. Atherosclerosis and inflammatory disease. N Eng J Med. 340(2):115-26.
Rothwell PM, Howard SC, Power DA. 2004 Fibrinogen Concentration and Risk of Ischemic Stroke and Acute Coronary Events in 5113 Patients With Transient Ischemic Attack and Minor Ischemic Stroke. Stroke. 35:2300-2305.
Sacco R.L., 2000. Pathogenesis, Classification and Epidemiology of Cerebrovascular Dissease. In: Rowland L.P. ed. Merrit’s Neurology. 1oth ed. Pp. 217 – 229. Lippincott Williams and Wilkins. Philadelphia.
Sacco,R.L., Kasner,S.E., Broderick, J.P., Caplan, L.R.,Connors, J.J., Culebras, A. et al. 2013. An Updated Definition of Stroke for the 21st Century: A Statement for Healthcare Professionals from the American Heart Association/ American Stroke association. Stroke. 44:2064 – 2089.
Salaets K, Schliessman J, Speiser R, Tran AM, Wang E, Angerio A. 2006. Role of Endothelin-1 in Atherosclerosis. Goergetown Journal of Health Sciences. 3(1).
Sabeti S, Exner M, Mlekusch W, Amighi J.2005. Prognostic Impact of Fibrinogen in Carotid Atherosclerosis Nonspecific Indicator of Inflammation or Independent Predictor of Disease Progression? Stroke. 2005;36:1400-1404.
Sastroasmoro, S., Ismael,S .2011. Dasar-dasar Metodologi Penelitian Klinis. Edisi ke 4. Penerbit Sagung Seto. Jakarta.
Sehnal, E., Slany, J. 2002. Fibrinogen the key to familial CHD or just another shadow in Plato’s Allegory?. European Heart Journal. 23: 1231-1233.
Shinohara,Y., Katayama,Y., Uchiyama,S., Yamaguchi,T., Honda,S., Matsuoka,K. Et al. 2010. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomized non inferiority trial. http: www.thelancet.com/neurology, 11 september 2010.
Sjahrir, H. 2003. Stroke Iskemik. Yandira Agung, Medan.
Smith EB, Keen GA, Grant A, Stirk C. 1990. Fate of fibrinogen in human arterial intima. Arteriosclerosis.,10:263-75.
Soekidjo, N. 2010. Metodologi Penelitian Kesehatan. Peneribit Rineka Cipta. Jakarta.
Stout, R.W., Crawford, V. 1991. Seasonal variations in fibrinogen concentrations among elderly people. Lancet. 338:9-13.
Sturm, J.W., Donnan, G.A., Dewey,H.M., Macdinnell, R.A., Gilligan, A.K. Srikanth, V. et al. 2004. Quality of Life after Stroke: The North East Melbourne Stroke Incidence Study. Stroke. 35 : 2340-2345.
Sulter, G., Steen, C. and Keyser, J.D. 1999. Use of Barthel Index and Modified Rankin Scale in Acute Stroke Trials. Stroke, 30: 1538-1541.
Szmitko, P.E., Wang,C., Weisel,R.D., De Almeida,J.R., Anderson,T.J., Verma S. 2003. The role inflamation in aterosclerosis. Circulation.108: 1917-1923.
Thrift, A.G., Dewey, H.M., Macdonell, R.A.L., Mc Neil,J.J., Donnan, G.A. 2001. Incidence of the major Stroke subtypes : Initial finding from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke.32:1732-1738.
Tsimikas, S, Bergmark,C., Beyer, R.W. 2003. Temporal increases in Plasma Markers of Oxidized Low- Density Lipoprotein Strongly reflect the presence of Acute Coronary Syndrome. Am. Coll. Cardiol,41: 360-370.
Van Oijen, M., E. Y. L. Cheung.2008.. Haplotypes of the fibrinogen gene and cerebral small vessel disease: the Rotterdam scan study." Journal of Neurology Neurosurgery and Psychiatry 79(7): 799-803.
Van’t Hooft, F.M., Von Bahr, J.F., Silveira, A., Iliadon, A., Eriksson, P., Hamston, A. 1999. Two Common, Functional Polymorphisms in Promoter Region of the -Fibrinogen gene contribute to Regulation to Plasma Fibrinogen concentration. Arterioscler Thromb Vasc Biol. 19: 3063-3070.
Vierra, A.J. and Garrett, J.M. 2005. Understanding Interobserver Agreement: The Kappa Statistic. Fam Med. 37(5): 360-3.
Voetsch B., Loscalzo J., 2004. Genetic Determinants of Artrial Thrombosis. Arterioscler Thromb Vasc Biol. 24: 216 – 229.
Warlow C.P. 1997. Stroke a practical guide to management. 2nd ed. Great Britain: Blackwell Science Ltd.
Welch, G.N., Loscalzo,J. 1998. Homocycteine and atherotmbosis. N. Eng. J. Med. 339(7):477.
Weimar ,C., Kurth, T., Kraywinkel, K, Wagner, M., Busse, O., Haberl, R.L., Dienner, H.C. 2002. Assessment of fuctioning and disability after Ischemic Stroke. Stroke.33: 2053 – 2059.
Whiteley, W., Wardlaw,J., Dennis, M., Lowe, G., Rumley, A., Sattar, A., et al. 2012. The Use of Blood Biomarkers to Predict Poor Outcome After Acute Transient Ischemic Attack or Ischemic Stroke. Stroke.43: 86-91.
Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G.1984 Fibrinogen as a risk factor for stroke and Myocardial Infarction. N Engl J Med 311:501–505.
Wilterdink,J.L., Bendixen, B., Adams, H.P., Woolson, R.F., Clarke,W.L.,Hansen, MD. 2001. Effect of Prior Aspirin use on Stroke Severity in The Trial of Org 10172 in Acute Stroke Treatment (TOAST). Stroke. 32: 2836-2840.
Wypasek E., Stepien E., Kot M., Plicner D., Kapelak B., Sadowski J. et al. 2012. Fibrinogen Beta-Chain-C148T Polymorphism is associated with Increased Fibrinogen, C-Reactive Protein and Interleukin-6 in Patients Undergoing Coronary Artery Bypass Grafting. Inflamation, 35(2): 429-435.
Yarnell J.w., Baker, I.A., Sweetnam P.M., Bainton D., O’Brien J.R., Whitehead P.J., et al. 1991. Fibrinogen, Viscosity, and White Blood Cell Count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation, 83: 836-844.
Yatsu, F.M., Villar-Cordova, C. 1998. Atherosclerosis. In: Barnett H.J.M.(editor). Stroke, Pathophysiology, diagnosis and management. 3rd ed. New York. Churchill Livingstone.p. 29-37.
Yong, M. Kaste, M. 2008. Dynamic of Hyperglicemia as A predictor of Stroke Outcome in The ECSS-Trial. Stroke. 39: 2749-2755.
